US Stock MarketDetailed Quotes
TCBP TC BioPharm
- 1.3100
- -0.0100-0.76%
Close Nov 1 16:00 ET
647.81KMarket Cap-6P/E (TTM)
1.3600High1.2500Low216.33KVolume1.3200Open1.3200Pre Close283.39KTurnover43.99%Turnover RatioLossP/E (Static)494.51KShares138.000052wk High0.46P/B644.16KFloat Cap1.122652wk Low--Dividend TTM491.73KShs Float35000.0000Historical High--Div YieldTTM8.33%Amplitude1.1220Historical Low1.3090Avg Price1Lot Size
TC BioPharm Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q3)Sep 30, 2021 | (FY)Dec 31, 2020 | (Q4)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 17.27%-2.41M | 31.04%-10.54M | -3.64M | -2.91M | -174.01%-15.29M | -62.62%-5.58M | -67.45%-2.55M | -1.09M | 49.00%-3.43M | -1.52M |
| Net income from continuing operations | -423.20%-3.32M | -349.68%-5.91M | --288.49K | ---634.91K | 91.23%-1.31M | -126.00%-14.98M | -168.52%-4.52M | ---7.3M | 3.83%-6.63M | ---1.68M |
| Operating gains losses | 99.64%-11.45K | 49.97%-7.97M | ---4.96M | ---3.17M | -475.26%-15.94M | 224,465.20%4.25M | 45,841.19%271.05K | --3.97M | -97.40%1.89K | --590 |
| Depreciation and amortization | -29.81%127.02K | -17.75%633.01K | --258.81K | --180.97K | -24.92%769.6K | -4.66%1.03M | -6.78%250.35K | --249.31K | 18.88%1.08M | --268.56K |
| Other non cash items | ---- | -89.40%717.41K | --557.57K | --231.54K | 96.85%6.77M | 1,081.49%3.44M | 2,692.96%1.92M | --1.15M | 14.80%291.03K | --68.81K |
| Change In working capital | -96.11%13.13K | 122.96%1.54M | --307.02K | --337.21K | -2,789.09%-6.7M | -402.61%-232.08K | 14.28%-410.55K | ---270.81K | 104.23%76.69K | ---478.92K |
| -Change in receivables | 72.31%-110.74K | 316.24%676.41K | --708.75K | ---400K | 47.13%-312.8K | -134.22%-591.62K | -953.54%-447.53K | ---244.18K | 569.96%1.73M | --52.43K |
| -Change in prepaid assets | -61.73%127.24K | -3,300.45%-1.28M | ---- | --332.51K | ---37.5K | ---- | ---- | ---- | ---- | ---- |
| -Change in payables and accrued expense | -95.17%21.61K | 216.88%2.27M | ---111.94K | --447.42K | -183.16%-1.94M | 616.02%2.34M | 1,548.98%531.65K | --468.04K | 884.71%326.56K | ---36.69K |
| -Change in other current assets | 4.00%48.06K | -3.60%189.51K | ---- | --46.21K | --196.58K | ---- | ---- | ---- | ---- | ---- |
| -Change in other current liabilities | 17.88%-73.03K | 57.53%-323.71K | ---- | ---88.93K | ---762.15K | ---- | ---- | ---- | ---- | ---- |
| -Change in other working capital | ---- | ---- | ---- | ---- | -94.30%-3.84M | 0.00%-1.98M | 0.00%-494.67K | ---494.66K | 2.56%-1.98M | ---494.67K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 17.27%-2.41M | 31.04%-10.54M | ---3.64M | ---2.91M | -174.01%-15.29M | -62.62%-5.58M | -67.45%-2.55M | ---1.09M | 49.00%-3.43M | ---1.52M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 96.13%-5.62K | 32.69%-208.79K | -71.59K | -145.23K | -116.58%-310.2K | 30.13%-143.22K | 1.87%-52.04K | -30.27K | 90.67%-204.99K | -53.03K |
| Net PPE purchase and sale | --0 | 40.58%-110.35K | ---38.68K | ---120.18K | -827.03%-185.71K | 42.60%-20.03K | -80.48%-8.75K | ---9.34K | 98.28%-34.9K | ---4.85K |
| Net intangibles purchase and sale | 77.57%-5.62K | 20.93%-98.44K | ---32.91K | ---25.05K | -1.05%-124.49K | 27.57%-123.19K | 10.15%-43.29K | ---20.94K | -0.02%-170.09K | ---48.18K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 96.13%-5.62K | 32.69%-208.79K | ---71.59K | ---145.23K | -116.58%-310.2K | 30.13%-143.22K | 1.87%-52.04K | ---30.27K | 90.67%-204.99K | ---53.03K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -76.42%932.56K | -54.32%8.52M | 43.81K | 3.95M | 185.87%18.65M | 90.22%6.53M | 2,538.45%2.61M | 2.36M | 4.78%3.43M | -107.22K |
| Net issuance payments of debt | ---- | --0 | ---- | ---- | -141.75%-2.61M | 1,607.73%6.26M | 2,538.45%2.61M | --2.36M | -406.39%-415.27K | ---107.22K |
| Net common stock issuance | -98.63%19.77K | 24.24%4.19M | ---998.99K | --1.44M | 1,081.97%3.37M | -92.69%285.11K | 100.76%1 | --0 | 24.24%3.9M | ---131 |
| Proceeds from stock option exercised by employees | -63.09%986.77K | -72.74%5.13M | --1.22M | --2.67M | --18.81M | --0 | ---- | ---- | --0 | ---- |
| Net other financing activities | 53.46%-73.98K | 12.64%-793.75K | --1 | ---158.97K | -4,193.96%-908.6K | 60.28%-21.16K | --0 | --0 | ---53.27K | --131 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -76.42%932.56K | -54.32%8.52M | --43.81K | --3.95M | 185.87%18.65M | 90.22%6.53M | 2,538.45%2.61M | --2.36M | 4.78%3.43M | ---107.22K |
| Net cash flow | ||||||||||
| Beginning cash position | -48.78%2.46M | 206.89%4.81M | --5.71M | --4.81M | 109.45%1.57M | -21.80%748.02K | -36.18%1.55M | --287.99K | -85.66%956.5K | --2.43M |
| Current changes in cash | -265.04%-1.48M | -173.21%-2.23M | ---3.67M | --897.76K | 280.92%3.05M | 487.67%800.89K | 100.93%15.62K | --1.24M | 96.35%-206.59K | ---1.68M |
| Effect of exchange rate changes | ---- | -158.83%-112.17K | ---- | ---- | 972.22%190.65K | 1,040.30%17.78K | 150.17%296 | --18.76K | 96.95%-1.89K | ---590 |
| End cash Position | -82.81%980.96K | -48.78%2.46M | --1.92M | --5.71M | 206.89%4.81M | 109.45%1.57M | 109.45%1.57M | --1.55M | -21.80%748.02K | --748.02K |
| Free cash flow | 21.01%-2.41M | 31.32%-10.75M | ---3.71M | ---3.06M | -173.53%-15.66M | -57.40%-5.72M | -65.11%-2.6M | ---1.12M | 59.26%-3.64M | ---1.57M |
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data